Great Basin Scientific is a molecular diagnostics company dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. With a compelling customer-centric business model, no-cost instrumentation, simple workflow, low-cost assays and support included at no-charge, Great Basin removes the barriers typically found in adopting molecular diagnostics.
GBS technology empowers health providers with answers to quickly and accurately define a clear treatment path for improved patient outcomes, shorter hospital stays, and dollars saved in hospitalization costs per patient.
GBS vision is to make molecular diagnostic testing so easy and cost-effective that every patient will be tested for every serious infection, thereby reducing misdiagnoses and significantly limiting the spread of infectious disease.
Great Basin Issued Second U.S. Patent for PCR Amplification Suppressor
Posted on May 24, 2017 in Featured, Investors, Press Releases
New patent extends protection to all the Company’s assays; Company to explore licensing opportunities with non-competing entities
Salt Lake City, May 24, 2017 – Great Basin Scientific, Inc. (OTCQB: GBSN), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent 9,657,353 for the Company’s amplification suppressor. This patent is the second U.S. patent relating to Great Basin’s amplification suppressor technology, expanding the Company’s protection to assays, kits, and products. The protection afforded by this patent allows the Company to explore licensing of the technology to applications such as medical research, food safety, veterinary, and more.
“Environmental contamination by Staphylococcus species or any other bacteria environmental contaminant of clinical samples—producing false positive results—is a problem that has stymied the molecular diagnostics industry since its beginning, which was the impetus for our development of this technology,” said Robert D. Jenison, chief technology officer of Great Basin Scientific. “We believe our amplification suppressor is an important scientific advancement in its ability to fully suppress non-life-threatening environmental contaminants from a clinical sample. This important technology enables us to seek licensing opportunities with molecular diagnostics companies that operate outside of our market niche, and aligns with our growth strategy to broaden our revenue stream.”
Data Demonstrating Efficacy of Stool Bacterial Pathogens Panel Presented at ASM Microbe 2017
Posted on June 1, 2017 in Featured, Investors, Press Releases
Four posters describing the Company’s platform to be presented, including a third-party clinical study poster of the Stool Bacterial Pathogens Panel
Salt Lake City, June 1, 2017 – Great Basin Scientific, Inc. (OTCQB: GBSN), a molecular diagnostics company, announced today that it will present three posters describing the reliability and effectiveness of its diagnostic platform to attendees of ASM Microbe 2017, which is being held June 1-5, 2017 in New Orleans. Additionally, Dr. Paul Granato from the Laboratory Alliance of Central New York will present a poster summarizing the results of a multi-site independent clinical study evaluating the Company’s Stool Bacterial Pathogens Panel, which is awaiting 510(k) clearance from the U.S. Food and Drug Administration (FDA). In the independent study, the Company’s Stool Bacterial Pathogens Panel is shown to process results in approximately two hours with superior detection rates of over 97% compared to 51% for conventional culture and EIA methods.
“We are very pleased to continue to show a growing body of data demonstrating how our cost-effective, sample-to-result platform can support our customers’ needs and, we believe, provide better patient outcomes,” said Ryan Ashton, co-founder and chief executive officer of Great Basin Scientific. “We are particularly proud of the results we have seen from our highly-anticipated Stool Bacterial Pathogens Panel, which we believe addresses the testing and reimbursement challenges affecting our healthcare system. Data shows our panel produces highly accurate and fast diagnosis in a multiplex assay that detects the top 90-95 percent of foodborne infections; Salmonella species, Shigella species, Shiga Toxin-producing E. coli (stx1, stx 2, O157 serotype-specific genes), and Campylobacter species (C. jejuni and C. coli).”
About ASM
The American Society for Microbiology (ASM) is the largest single life science society, composed of over 47,000 scientists and health professionals. ASM’s mission is to promote and advance the microbial sciences. ASM advances the microbial sciences through conferences, publications, certifications, and educational opportunities. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry, and clinical settings. Additionally, ASM promotes a deeper understanding of the microbial sciences to diverse audiences. For more information about ASM, please visit http://www.asm.org/.
Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect future operating results and financial position, including but not limited to statements regarding the Company’s ability to license its technology, the ability to add revenue from such license arrangements and its ability to expand the use of the amplification suppressor technology in future tests and panels. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) limited operating history and history of losses; (ii) ability to develop and commercialize new products and the timing of commercialization; (iii) ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 and in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2017. These forward-looking statements speak only as of the date hereof, and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.
Source: The Company, Daily Stock Deals, OxBridge Research, OTC Stock Wire
